{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T14:37:14Z","timestamp":1785854234888,"version":"3.56.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.cmi.2026.03.001","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T02:21:05Z","timestamp":1772850065000},"page":"936-941","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["How to safely discontinue antifungal treatment in invasive pulmonary aspergillosis?\u2013clinical considerations in haematology"],"prefix":"10.1016","volume":"32","author":[{"given":"Jannik","family":"Stemler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanne","family":"Sprute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Koehler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver A.","family":"Cornely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2026.03.001_bib1","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2026.03.001_bib2","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1086\/514341","article-title":"Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)","volume":"44","author":"Cornely","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2026.03.001_bib3","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2026.03.001_bib4","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0140-6736(21)00219-1","article-title":"Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial","volume":"397","author":"Maertens","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2026.03.001_bib5","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1086\/341401","article-title":"A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients","volume":"35","author":"Bowden","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2026.03.001_bib6","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1086\/590566","article-title":"Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria","volume":"47","author":"Segal","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2026.03.001_bib7","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/myc.12960","article-title":"Defining breakthrough invasive fungal infection-Position paper of the mycoses study group education and research consortium and the European Confederation of Medical Mycology","volume":"62","author":"Cornely","year":"2019","journal-title":"Mycoses"},{"key":"10.1016\/j.cmi.2026.03.001_bib8","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/jac\/dkab317","article-title":"When to change treatment of acute invasive aspergillosis: an expert viewpoint","volume":"77","author":"Slavin","year":"2021","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.cmi.2026.03.001_bib9","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/cid\/ciw444","article-title":"Executive Summary: Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clinical infectious diseases\u202f: an official publication of the Infectious Diseases Society of America"},{"key":"10.1016\/j.cmi.2026.03.001_bib10","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2026.03.001_bib11","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/myc.13056","article-title":"Invasive pulmonary aspergillosis treatment duration in haematology patients in Europe: an EFISG, IDWP-EBMT, EORTC-IDG and SEIFEM survey","volume":"63","author":"Lanternier","year":"2020","journal-title":"Mycoses"},{"key":"10.1016\/j.cmi.2026.03.001_bib12","doi-asserted-by":"crossref","first-page":"ofae201","DOI":"10.1093\/ofid\/ofae201","article-title":"Antifungal treatment duration in hematology patients with invasive mold infections: a real-life update","volume":"11","author":"Portillo","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2026.03.001_bib13","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/s41409-025-02545-x","article-title":"Antifungal prescription and stewardship in hematology and hematopoietic stem cell transplantation units worldwide: an international survey of EHA-SWG Infections in Hematology","volume":"60","author":"Gavriilaki","year":"2025","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cmi.2026.03.001_bib14","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/jac\/dkae103","article-title":"Triazole antifungal drug interactions-practical considerations for excellent prescribing","volume":"79","author":"Lewis","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2026.03.001_bib15","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.1016\/S2352-3026(22)00073-4","article-title":"Antifungal prophylaxis in adult patients with acute myeloid leukaemia treated with novel targeted therapies: a systematic review and expert consensus recommendation from the European Hematology Association","volume":"9","author":"Stemler","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.cmi.2026.03.001_bib16","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s00277-020-04107-1","article-title":"Antifungal prophylaxis and novel drugs in acute myeloid leukemia: the midostaurin and posaconazole dilemma","volume":"99","author":"Stemler","year":"2020","journal-title":"Ann Hematol"},{"key":"10.1016\/j.cmi.2026.03.001_bib17","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1093\/cid\/ciz1195","article-title":"How long do we need to treat an invasive mold disease in hematology patients? Factors influencing duration of therapy and future questions","volume":"71","author":"Fern\u00e1ndez-Cruz","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2026.03.001_bib18","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1007\/s10067-025-07425-9","article-title":"CD3 + CD4 + T cells counts reflect the severity and prognosis of invasive pulmonary aspergillosis in patients with connective tissue disease-associated interstitial lung disease","volume":"44","author":"Shi","year":"2025","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.cmi.2026.03.001_bib19","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1378\/chest.114.1.131","article-title":"Risk factors and outcomes associated with identification of Aspergillus in respiratory specimens from persons with HIV disease. Pulmonary Complications of HIV Infection Study Group","volume":"114","author":"Wallace","year":"1998","journal-title":"Chest"},{"key":"10.1016\/j.cmi.2026.03.001_bib20","doi-asserted-by":"crossref","first-page":"ofae114","DOI":"10.1093\/ofid\/ofae114","article-title":"Serial bronchoalveolar lavage fluid aspergillus galactomannan and treatment response in invasive pulmonary aspergillosis","volume":"11","author":"Friedman","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2026.03.001_bib21","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s10928-017-9509-1","article-title":"Prognostic value of galactomannan: current evidence for monitoring response to antifungal therapy in patients with invasive aspergillosis","volume":"44","author":"Kovanda","year":"2017","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.cmi.2026.03.001_bib22","doi-asserted-by":"crossref","first-page":"108272","DOI":"10.1016\/j.ijid.2025.108272","article-title":"Sequential serum galactomannan as outcome marker for invasive aspergillosis-An exploratory study from the FungiScope registry","volume":"163","author":"T\u00f6bben","year":"2025","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.cmi.2026.03.001_bib23","doi-asserted-by":"crossref","first-page":"562.e1","DOI":"10.1016\/j.cmi.2016.01.027","article-title":"Aspergillus PCR in serum for the diagnosis, follow-up and prognosis of invasive aspergillosis in neutropenic and nonneutropenic patients","volume":"22","author":"Imbert","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2026.03.001_bib24","doi-asserted-by":"crossref","first-page":"120553","DOI":"10.1016\/j.cca.2025.120553","article-title":"Monitoring treatment response using serial PTX3 levels in chronic and invasive pulmonary aspergillosis","volume":"578","author":"Huang","year":"2026","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.cmi.2026.03.001_bib25","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s00259-018-4192-z","article-title":"Role of FDG PET\/CT in monitoring treatment response in patients with invasive fungal infections","volume":"46","author":"Ankrah","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.cmi.2026.03.001_bib26","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1093\/infdis\/jiae409","article-title":"Serial fluorodeoxyglucose positron emission tomography-computed tomography (18FDG-PET-CT) in assessing treatment response in chronic pulmonary aspergillosis","volume":"231","author":"Sehgal","year":"2025","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cmi.2026.03.001_bib27","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1093\/jac\/dkn027","article-title":"Risk factors for breakthrough invasive fungal infection during secondary prophylaxis","volume":"61","author":"Cornely","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2026.03.001_bib28","doi-asserted-by":"crossref","first-page":"16078","DOI":"10.1038\/s41598-020-73098-w","article-title":"Short course of voriconazole therapy as a risk factor for relapse of invasive pulmonary aspergillosis","volume":"10","author":"Shin","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.cmi.2026.03.001_bib29","doi-asserted-by":"crossref","first-page":"102393","DOI":"10.1016\/j.eclinm.2023.102393","article-title":"Influence of invasive aspergillosis during acute leukaemia treatment on survival after allogeneic stem cell transplantation: a prospective study of the EBMT Infectious Diseases Working Party","volume":"67","author":"Penack","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.cmi.2026.03.001_bib30","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s10096-014-2302-9","article-title":"How to interpret serum levels of beta-glucan for the diagnosis of invasive fungal infections in adult high-risk hematology patients: optimal cut-off levels and confounding factors","volume":"34","author":"Hammarstr\u00f6m","year":"2015","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2026.03.001_bib31","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/myc.12432","article-title":"1,3-\u00df-D-glucan concentrations in blood products predict false positive post-transfusion results","volume":"59","author":"Liss","year":"2016","journal-title":"Mycoses"},{"key":"10.1016\/j.cmi.2026.03.001_bib32","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3390\/jof6010036","article-title":"Baseline chest computed tomography as standard of care in high-risk hematology patients","volume":"6","author":"Stemler","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.cmi.2026.03.001_bib33","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ijantimicag.2009.06.025","article-title":"Efficacy of caspofungin and itraconazole as secondary antifungal prophylaxis: analysis of data from a multinational case registry","volume":"34","author":"Vehreschild","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2026.03.001_bib34","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1056\/NEJM200402263500923","article-title":"Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants","volume":"350","author":"Marty","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2026.03.001_bib35","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/myc.12731","article-title":"Isavuconazole shortens the QTc interval","volume":"61","author":"Mellinghoff","year":"2018","journal-title":"Mycoses"},{"key":"10.1016\/j.cmi.2026.03.001_bib36","doi-asserted-by":"crossref","first-page":"5026","DOI":"10.1128\/AAC.01031-09","article-title":"Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species","volume":"53","author":"Mann","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2026.03.001_bib37","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1093\/jac\/dks189","article-title":"Invasive fungal breakthrough infections, fungal colonization and emergence of resistant strains in high-risk patients receiving antifungal prophylaxis with posaconazole: real-life data from a single-centre institutional retrospective observational study","volume":"67","author":"Auberger","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2026.03.001_bib38","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000547073","article-title":"Therapeutic drug monitoring: a driver to precision medicine for patients with hematological malignancies","volume":"70","author":"Stemler","year":"2025","journal-title":"Chemotherapy"},{"key":"10.1016\/j.cmi.2026.03.001_bib39","doi-asserted-by":"crossref","first-page":"ii21","DOI":"10.1093\/jac\/dkac353","article-title":"Liposomal amphotericin B-the future","volume":"77","author":"Hoenigl","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2026.03.001_bib40","doi-asserted-by":"crossref","first-page":"ii11","DOI":"10.1093\/jac\/dkac352","article-title":"Liposomal amphotericin B-the present","volume":"77","author":"Maertens","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2026.03.001_bib41","doi-asserted-by":"crossref","first-page":"697330","DOI":"10.3389\/fphar.2021.697330","article-title":"Adverse effects associated with currently commonly used antifungal agents: a network meta-analysis and systematic review","volume":"12","author":"Yang","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.cmi.2026.03.001_bib42","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s40265-021-01611-0","article-title":"The antifungal pipeline: fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin","volume":"81","author":"Hoenigl","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.cmi.2026.03.001_bib43","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/S1473-3099(25)00224-5","article-title":"Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study","volume":"25","author":"Maertens","year":"2025","journal-title":"Lancet Infect Dis"},{"issue":"25","key":"10.1016\/j.cmi.2026.03.001_bib44","article-title":"The changing epidemiology of invasive mould diseases in immunosuppressed patients: what, why, how?","volume":"S1198-743X","author":"Apostolopoulou","year":"2025","journal-title":"Clin Microbiol Infect"},{"issue":"25","key":"10.1016\/j.cmi.2026.03.001_bib45","article-title":"The future of invasive mould infections-challenges, novelties and changing paradigms","volume":"S1198-743X","author":"Stemler","year":"2025","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2026.03.001_bib46","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11046-023-00822-1","article-title":"The Cologne ECMM Excellence Center: a two-year analysis of external consultation service for invasive fungal infections","volume":"189","author":"Salmanton-Garc\u00eda","year":"2024","journal-title":"Mycopathologia"},{"key":"10.1016\/j.cmi.2026.03.001_bib47","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/myc.13076","article-title":"European confederation of medical mycology expert consult-An ECMM excellence center initiative","volume":"63","author":"Koehler","year":"2020","journal-title":"Mycoses"},{"issue":"26","key":"10.1016\/j.cmi.2026.03.001_bib48","article-title":"Which trial do we need? Defining the optimal duration of antifungal therapy for invasive pulmonary aspergillosis","volume":"S1198-743X","author":"Desoubeaux","year":"2026","journal-title":"Clin Microbiol Infect"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X26001060?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X26001060?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T11:48:33Z","timestamp":1778759313000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X26001060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1198743X26001060"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2026.03.001","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How to safely discontinue antifungal treatment in invasive pulmonary aspergillosis?\u2013clinical considerations in haematology","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2026.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}